Bpifrance

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. Its flagship product, the CAVI-T, is an asymmetrical intranasal balloon designed to manage spontaneous or postoperative bleeding through low-pressure compression, tailored to the unique anatomy of the nasal cavity. This device also features an active balloon that minimizes biofilm formation, targets specific bacteria, and promotes healing. Additionally, Dianosic is developing an Active Resorbable Intranasal Scaffold device aimed at treating chronic sinusitis in patients who do not respond to conventional drug therapies. These advancements enable healthcare professionals to monitor patients remotely, enhancing post-operative care and overall treatment efficacy.

Apmonia Therapeutics is focused on developing next-generation peptide-based therapies aimed at improving treatment options for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. The company concentrates on targeting the tumor microenvironment, which plays a crucial role in cancer progression. By creating innovative drugs, Apmonia Therapeutics seeks to enhance therapeutic strategies for solid tumors and provide new perspectives in cancer treatment. Their approach includes the development of personalized immunotherapy solutions that utilize proprietary therapeutic peptides, ultimately aiming to improve the quality of life for patients battling cancer and assisting researchers in their efforts to advance cancer therapies.

Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in the resolution of inflammation. The company develops treatments based on monoclonal antibodies by treating human mucosal inflammatory diseases by inhibiting a target that could be implied in the early inflammatory process and the recruitment of innate immunity cells, enabling healthcare providers to cure their patients.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.

Priothera Ltd is a clinical-stage company focused on developing orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. Founded in 2020 and based in Dublin, Ireland, with an additional location in Saint Louis, France, the company seeks to improve patient outcomes by enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. Its lead product, mocravimod, is designed to reduce the egress of specific T cell subsets from lymphatic tissues, thereby providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects. Through this innovative approach, Priothera aims to deliver significant advancements in the treatment of patients with blood cancers.

Brenus Pharma is focused on developing cell-based immunotherapies aimed at treating solid tumors. The company utilizes an allogeneic platform to create anti-cancer cell vaccines, which leverage the patient's immune system to combat cancer and reduce the risk of treatment resistance. Their approach emphasizes generating multiple candidate therapies efficiently, allowing for cost-effective scaling and integration with existing treatment standards. With a strong intellectual property portfolio and a team of experienced professionals, including renowned oncologists, Brenus Pharma seeks to educate the immune system to recognize and respond to tumor-associated and tumor-specific antigens, enhancing the effectiveness of chemotherapy and radiotherapy in cancer care.

Developer a biotechnology platform intended to improve the quality of life of patients. The company's platform specializes in developing an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy with cancer therapy and senescence, enabling patients to have proper health and treatment.

Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

Lysogene S.A. is a biotechnology company based in Neuilly-sur-Seine, France, focused on the research and clinical development of gene therapy for neurodegenerative disorders. Founded in 2009, the company is advancing several clinical programs, including LYS-SAF302, currently in Phase II/III trials for the treatment of mucopolysaccharidosis type IIIA, and LYS-GM101, which is in Phase I/II trials for GM1 gangliosidosis. Lysogene is also engaged in a collaborative research effort with the Weizmann Institute of Science to develop a novel AAV gene therapy approach targeting neuronopathic Gaucher disease, Parkinson's disease, and other conditions. The company aims to enhance the health outcomes of patients suffering from life-threatening, incurable disorders by utilizing AAV vectors that effectively deliver genetic material to the central nervous system.

Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Provepharm life Solutions is a truly unique life sciences research and pharma company, dedicated to a new era of discovery. We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. As PROVEPHARM LIFE SOLUTIONS, we are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care.

PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.

Seekyo SAS is a biotechnology company based in Poitiers, France, established in 2018. The company specializes in developing innovative treatment options for cancer patients, focusing on the creation of smart molecular systems. These systems are designed to transport potent anticancer agents selectively, targeting the microenvironment of solid tumors while minimizing harm to healthy tissues. Seekyo's approach utilizes advanced technologies such as antibody drug conjugates and small molecule drug conjugates, which specifically recognize cancer cell surface markers and tumor microenvironment characteristics. This allows for the controlled release of therapeutic agents directly at the tumor site, enhancing treatment efficacy and reducing adverse effects. By prioritizing the safety and effectiveness of chemotherapy, Seekyo aims to improve the overall treatment experience for cancer patients.

OncoDiag is a French biotechnology company located in Normandy, dedicated to creating non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, the Urotest, is a urine test approved for the diagnosis and monitoring of bladder cancer. In addition to the Urotest, OncoDiag is developing Colodiag, a test focused on the early identification of colorectal cancer, and other diagnostic tools, including a tissue-based test for predicting non-evolutive localized prostate cancer. Through its innovative testing kits, OncoDiag aims to enhance cancer diagnostics, allowing healthcare professionals to provide timely and effective patient care.

CVasThera is a biopharmaceutical company focused on creating innovative therapies for cardiovascular and bowel diseases, particularly targeting conditions such as Crohn's disease. The company has secured an exclusive global license for two patents that emerged from four years of collaborative research involving the French National Institute of Health and Medical Research and the École des Mines d’Albi. By leveraging this research, CVasThera aims to provide effective treatment options for patients experiencing moderate to severe flare-ups, especially those reliant on corticosteroids.

Kayentis SAS specializes in electronic clinical outcome assessment (eCOA) and electronic data capture solutions, primarily serving pharmaceutical companies and clinical trial organizations. Founded in 2003 and headquartered in Meylan, France, with additional offices in Boston and Tokyo, the company provides a range of tools designed to streamline clinical trials. Their offerings include Clin'form, a web portal for data management; ePEN, a data capture solution that reduces study duration and costs; and Kayentis Tablet for site-based eClinRO and ePRO data collection. Kayentis also offers project management, design and validation services, training, and comprehensive data management, enhancing the efficiency of clinical trial data collection for sponsors and operators.

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.

AlgoTherapeutix SAS is a biotechnology company founded in 2018 and located in Suresnes, France, focused on developing innovative topical treatments for complex pain conditions. The company's primary product, ATX01, is designed to alleviate peripheral neuropathic pain caused by chemotherapy. By targeting the damaged nerve fibers in the skin, AlgoTherapeutix aims to provide effective pain relief while minimizing the systemic side effects associated with oral medications. The company's approach also addresses other pain syndromes, such as erythromelalgia, thereby offering medical practitioners new options to enhance patient care for those suffering from chemotherapy-induced peripheral neuropathy.

Braintale develops and distributes accessible and effective diagnosis and prognosis tools for brain injured patients.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

SparingVision SAS is a biotechnology company based in Paris, France, focused on discovering and developing gene therapy-based treatments for blinding inherited retinal diseases. Founded in 2016, the company is working on SPVN06, a gene-independent therapy aimed at treating retinitis pigmentosa, the most common form of inherited retinal degeneration. This condition affects nearly 2 million people globally and currently lacks comprehensive treatment options for its various genetic forms. SparingVision’s efforts aim to provide innovative solutions for patients suffering from these debilitating diseases, enabling healthcare professionals to offer improved care for those at risk of blindness.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.

Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. Its flagship product, the CAVI-T, is an asymmetrical intranasal balloon designed to manage spontaneous or postoperative bleeding through low-pressure compression, tailored to the unique anatomy of the nasal cavity. This device also features an active balloon that minimizes biofilm formation, targets specific bacteria, and promotes healing. Additionally, Dianosic is developing an Active Resorbable Intranasal Scaffold device aimed at treating chronic sinusitis in patients who do not respond to conventional drug therapies. These advancements enable healthcare professionals to monitor patients remotely, enhancing post-operative care and overall treatment efficacy.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Syndivia SAS develops antibody-drug conjugates (ADC) for cancer treatment. The company provides therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks. It offers lead programs such as SDV1001 for pancreatic cancer and colorectal cancer and SDV1101 for breast cancer and liposarcoma. Syndivia SAS was incorporated in 2014 and is based in Illkirch-Graffenstaden, France.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Aelis Farma S.A.S. is a biotechnology company based in Bordeaux, France, established in 2013. The company specializes in the research and development of pregnenolone derivatives aimed at treating cannabis addiction. Aelis Farma is recognized for its innovative approach in developing signaling-specific therapeutics that target G protein-coupled receptors (GPCRs), particularly the CB1 receptor, which is widely expressed in the brain. By focusing on these receptors, Aelis Farma aims to create treatments that can selectively modulate signaling pathways, minimizing unwanted side effects commonly associated with conventional GPCR-targeting drugs. The company's work addresses critical needs in the treatment of brain diseases and addiction.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

AlgoTherapeutix SAS is a biotechnology company founded in 2018 and located in Suresnes, France, focused on developing innovative topical treatments for complex pain conditions. The company's primary product, ATX01, is designed to alleviate peripheral neuropathic pain caused by chemotherapy. By targeting the damaged nerve fibers in the skin, AlgoTherapeutix aims to provide effective pain relief while minimizing the systemic side effects associated with oral medications. The company's approach also addresses other pain syndromes, such as erythromelalgia, thereby offering medical practitioners new options to enhance patient care for those suffering from chemotherapy-induced peripheral neuropathy.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

NH TherAguix SAS, a clinical stage pharmaceutical company, develops nanomedicines for cancer, combining imaging, and radiotherapy. It offers AGuIX, a nanoparticle that is designed to improve the localization of solid tumors and the outcomes of radiation therapy by intravenous injection; allows the radiation therapy treatment for patient to determine the optimal moment to perform the irradiation; and allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues. The company was founded in 2015 and is based in Villeurbanne, France.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.

LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

MédiPôle Partenaires is a group of private clinics whose competence is particularly recognized in the fields of Medicine of Obstetric Surgery (MCO), Continuing Care and Rehabilitation (SSR) and Home Hospitalization (HAD).

MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.

Neovacs S.A. is a biotechnology company based in Paris, France, that specializes in the development of therapeutic vaccines known as "Kinoids" for treating autoimmune, inflammatory diseases, allergies, and cancer. Founded in 1993 by Professor Daniel Zagury, the company aims to create innovative treatments that stimulate a natural polyclonal antibody response in patients, contrasting with traditional monoclonal antibody therapies. Neovacs' product pipeline includes IFNa Kinoid, which is undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, along with preclinical developments targeting diabetes. Additionally, the company is working on VEGF-Kinoid for age-related macular degeneration and solid tumors, and IL-4/IL-13 Kinoid for allergies. Neovacs also collaborates with the Sunnybrook Research Institute to advance preclinical research on VEGF-Kinoid for colorectal and ovarian cancer. The company holds a broad patent portfolio and is recognized as a pioneer in the field of therapeutic vaccines.

TheraVectys SAS is a biotechnology company based in Paris, France, focused on developing a novel lentiviral vector platform for T-cell vaccines aimed at addressing critical unmet medical needs. Established in 2005, the company specializes in vaccines for the treatment and prevention of infectious diseases, virally-induced cancers, and other medical conditions. TheraVectys is currently advancing its lead product, a therapeutic vaccine for HIV/AIDS, which has demonstrated promising efficacy and safety in preclinical studies involving non-human primates. The company's technology is designed to modulate the immune response through gene transfer into dendritic cells, facilitating the development of both prophylactic and therapeutic immunotherapies.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

Voluntis, Inc. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. It offers Insulia, a prescription-only medical device that provides type 2 diabetes patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Voluntis, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

GamaMabs Pharma SA engages in the development of a new therapeutic antibody for the treatment of ovarian cancer. The company was founded in 2013 and is based in Toulouse, France.

Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.

Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.

Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.

Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.

Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.

Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.

Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.

Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.